Petroleo Brasileiro SA Petrobras
PBR
Ecopetrol
EC
Vale SA
VALE
D.R. Horton
DHI
KB Home
KBH
US Stock MarketDetailed Quotes
TARO Taro Pharmaceutical Industries
- 42.970
- 0.0000.00%
Trading Jul 25 09:30 ET
1.27BMarket Cap30.05P/E (TTM)
0.000High0.000Low0Volume0.000Open42.970Pre Close0.00Turnover0.00%Turnover Ratio30.05P/E (Static)29.50MShares45.76052wk High0.71P/B347.45MFloat Cap40.45052wk Low--Dividend TTM8.09MShs Float150.996Historical High--Div YieldTTM0.00%Amplitude1.637Historical Low--Avg Price1Lot Size
Taro Pharmaceutical Industries Key Stats
Quarterly+Annual
YOY
| (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.81%629.18M | 12.52%164.94M | 12.89%157.15M | 13.57%148.2M | 1.42%158.89M | 2.07%572.95M | 2.32%146.59M | 0.16%139.2M | -1.13%130.5M | 6.49%156.67M |
| Operating revenue | 9.81%629.18M | 12.52%164.94M | 12.89%157.15M | 13.57%148.2M | 1.42%158.89M | 2.07%572.95M | 2.32%146.59M | 0.16%139.2M | -1.13%130.5M | 6.49%156.67M |
| Cost of revenue | 6.43%324.23M | 9.41%77.55M | 2.81%77.26M | -10.70%74.6M | 26.31%94.81M | 13.57%304.63M | 7.52%70.88M | 19.39%75.16M | 19.44%83.54M | 8.13%75.06M |
| Gross profit | 13.65%304.96M | 15.43%87.39M | 24.72%79.88M | 56.73%73.6M | -21.47%64.08M | -8.46%268.32M | -2.12%75.71M | -15.77%64.05M | -24.31%46.96M | 5.03%81.61M |
| Operating expense | 13.11%283.47M | 18.32%78.61M | 1.96%64M | 28.05%68.86M | 6.47%72.01M | 48.98%250.61M | 18.49%66.43M | 60.77%62.77M | 48.64%53.78M | 83.14%67.63M |
| Selling and administrative expenses | 10.37%218.94M | 15.96%58.13M | 1.10%50.41M | 29.07%54.54M | -0.47%55.86M | 74.50%198.37M | 21.74%50.13M | 100.72%49.86M | 78.41%42.26M | 134.08%56.12M |
| -Selling and marketing expense | ---- | ---- | ---- | ---- | ---- | 100.07%113.28M | ---- | ---- | ---- | ---- |
| -General and administrative expense | ---- | ---- | ---- | ---- | ---- | 49.12%85.09M | ---- | ---- | ---- | ---- |
| Research and development costs | 23.53%64.54M | 25.59%20.48M | 5.28%13.59M | 24.33%14.33M | 40.29%16.15M | -4.21%52.24M | 9.50%16.31M | -9.11%12.91M | -7.79%11.52M | -11.15%11.51M |
| Operating profit | 21.29%21.49M | -5.28%8.78M | 1,141.83%15.88M | 169.55%4.74M | -156.68%-7.92M | -85.82%17.71M | -56.41%9.27M | -96.54%1.28M | -126.35%-6.82M | -65.72%13.98M |
| Net non-operating interest income expense | 169.51%56.19M | 97.04%15.83M | 135.07%15.5M | 225.23%13.97M | 465.42%10.89M | 154.67%20.85M | 1,071.43%8.04M | 215.41%6.59M | 81.19%4.3M | -36.69%1.93M |
| Non-operating interest income | 154.23%56.19M | 70.46%15.83M | 135.07%15.5M | 225.23%13.97M | 465.42%10.89M | 124.62%22.1M | 297.14%9.29M | 215.41%6.59M | 81.19%4.3M | -36.69%1.93M |
| Non-operating interest expense | ---- | ---- | ---- | ---- | ---- | -24.20%1.25M | ---- | ---- | ---- | ---- |
| Other net income (expense) | 1,521.65%4.99M | 172.88%1.61M | 51.04%1.97M | 55.83%-1.06M | 1,537.75%2.47M | 99.36%-351K | -80.67%590K | 209.76%1.3M | -302.11%-2.39M | 100.25%151K |
| Gain on sale of security | 100.32%9K | -25.37%-588K | -81.30%138K | 41.79%-1.62M | 808.50%2.08M | -241.71%-2.81M | -118.46%-469K | 235.66%738K | -1,156.06%-2.79M | -6.91%-294K |
| Special income (charges) | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | 102.32%4.98M | 107.55%2.2M | 224.51%1.83M | 43.29%566K | -12.36%390K | -41.76%2.46M | 106.43%1.06M | -43.13%563K | -83.12%395K | 15.89%445K |
| Income before tax | 116.33%82.67M | 46.53%26.23M | 263.54%33.34M | 459.35%17.66M | -66.11%5.44M | -50.92%38.21M | -28.45%17.9M | -76.78%9.17M | -116.70%-4.91M | 199.84%16.05M |
| Income tax | 125.57%28.8M | 1.48%11.15M | 588.83%13.14M | 533.71%9.11M | -332.67%-4.59M | -34.83%12.77M | 560.09%10.99M | -85.54%1.91M | -134.40%-2.1M | -26.56%1.97M |
| Net income | 111.70%53.87M | 118.11%15.08M | 178.16%20.21M | 403.84%8.55M | -28.74%10.03M | -56.33%25.45M | -74.77%6.91M | -72.39%7.27M | -112.06%-2.81M | 175.02%14.08M |
| Net income continuous Operations | 111.70%53.87M | 118.11%15.08M | 178.16%20.21M | 403.84%8.55M | -28.74%10.03M | -56.33%25.45M | -74.77%6.91M | -72.39%7.27M | -112.06%-2.81M | 175.02%14.08M |
| Minority interest income | 0 | |||||||||
| Net income attributable to the parent company | 111.70%53.87M | 118.11%15.08M | 178.16%20.21M | 403.84%8.55M | -28.74%10.03M | -56.33%25.45M | -74.77%6.91M | -72.39%7.27M | -112.06%-2.81M | 175.02%14.08M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 111.70%53.87M | 118.11%15.08M | 178.16%20.21M | 403.84%8.55M | -28.74%10.03M | -56.33%25.45M | -74.77%6.91M | -72.39%7.27M | -112.06%-2.81M | 175.02%14.08M |
| Basic earnings per share | 110.29%1.43 | 122.22%0.4 | 184.21%0.54 | 428.57%0.23 | -27.03%0.27 | -56.13%0.68 | -75.34%0.18 | -72.86%0.19 | -111.29%-0.07 | 174.00%0.37 |
| Diluted earnings per share | 110.29%1.43 | 122.22%0.4 | 184.21%0.54 | 428.57%0.23 | -27.03%0.27 | -56.13%0.68 | -75.34%0.18 | -72.86%0.19 | -111.29%-0.07 | 174.00%0.37 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.